rfk tirzepatide fda indications The peptide regulatory landscape in 2026 is in active flux. After the placed Impurity in Some Compounded Tirzepatide

I am excited to announce that we now have available the newest weight loss peptide: Retatrutide , which is currently in phase 3 trials with Lilly Pharmaceuticals and is expected to be FDA-approved by next year

Explain that although the medication has not been shown to cause thyroid disease, it may impact thyroid hormone levels or interact with thyroid medications

Microdosing is especially risky or ineffective for individuals with: These situations require consistent, controlled dosing

Lets look at the most common concerns these injections can effectively treat, from hormonal melasma to sun spots and post-acne marks